ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate is BPZE1, a live attenuated pertussis vaccine that is currently in Phase 2 and has successfully completed two Phase 1 human clinical trials. ILiAD Biotechnologies, LLC is a registered Delaware company founded in 2012.

Copyright 2013-2019 ILiAD Biotechnologies